Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Related Questions
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
What 24 hr urine calcium cut off value do you use for recommending parathyroidectomy in patients with asymptomatic hyperparathyroidism?
Is there a maximum duration for raloxifene use?
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Do you recommend the use of albumin-adjusted calcium measurement formulas to accurately assess calcium levels?
What is the likelihood of recovery of parathyroid gland function for patients who underwent total thyroidectomy, found to have embedded parathyroid glands intra-operatively and then subsequently had them re-implanted into neck muscle?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
